Sugi Predict

Sugi Predict / Compounds / SCHEMBL10508

SCHEMBL10508

SCHEMBL10508

CC(c1oc2ccccc2c(=O)c1-c1ccccc1)n1nc(-c2ccc3cn[nH]c3c2)c2c(N)ncnc21

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 18/20 0.61
▸ PIK3CG P48736 13/20 0.61
▸ SRC P12931 13/20 0.61
▸ ABL1 P00519 12/20 0.61
▸ PIK3CA P42336 12/20 0.61
▸ PIK3CB P42338 12/20 0.61
▸ PRKDC P78527 11/20 0.61
▸ EGFR P00533 10/20 0.61
▸ HCK P08631 10/20 0.61
▸ KDR P35968 10/20 0.61
▸ MTOR P42345 10/20 0.61
▸ EPHB4 P54760 10/20 0.61
▸ PIK3R1 P27986 1/20 0.55
▸ CSNK1E P49674 1/20 0.55
▸ PI4KB Q9UBF8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29651799 1.00 PIK3CD (0.61) PIK3CDPIK3CGSRCABL1PIK3CA
SCHEMBL29651778 0.93 PIK3CD (0.72) PIK3CDPIK3CGSRCABL1PIK3CA
SCHEMBL11354 0.93 PIK3CD (0.72) PIK3CDPIK3CGSRCABL1PIK3CA
SCHEMBL29651664 0.87 PIK3CD (0.61) PIK3CDPIK3CGSRCABL1PIK3CA
SCHEMBL10912 0.87 PIK3CD (0.61) PIK3CDPIK3CGSRCABL1PIK3CA
SCHEMBL29651820 0.85 PIK3CD (0.61) PIK3CDPIK3CGSRCABL1PIK3CA
SCHEMBL11693 0.85 PIK3CD (0.61) PIK3CDPIK3CGSRCABL1PIK3CA
SCHEMBL29651723 0.84 PIK3CD (0.67) PIK3CDPIK3CGSRCABL1PIK3CA
SCHEMBL129935 0.84 PIK3CD (0.67) PIK3CDPIK3CGSRCABL1PIK3CA
SCHEMBL29651763 0.82 PIK3CD (0.67) PIK3CDPIK3CGSRCABL1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US claimed
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 — — EP claimed
CN-117222413-A Methods and combinations for treating tumors 同润生物医药(上海)有限公司 2023-12-12 — — CN claimed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US claimed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 — — EP claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) 2024-05-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 — — EP disclosed
CN-117222413-A Methods and combinations for treating tumors 同润生物医药(上海)有限公司 2023-12-12 — — CN disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 — — US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885SRC 314/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885SRC 314/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885SRC 314/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A PIK3CD 103/4885PIK3CG 126/4885SRC 110/4885
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS PDCD1, PDCD1LG2, CD274 PIK3CD 116/4885PIK3CG 221/4885SRC 334/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885SRC 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.